1 / 51

Case Presentation Axillobifemoral Bypass

Christopher M. Baylis, SRNA Oregon Health and Science University. Case Presentation Axillobifemoral Bypass. Disclosure. I have no financial relationship with the manufacturer of a commercial product or provider of a commercial service that may be discussed in this presentation.

chione
Download Presentation

Case Presentation Axillobifemoral Bypass

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Christopher M. Baylis, SRNA Oregon Health and Science University Case PresentationAxillobifemoral Bypass

  2. Disclosure I have no financial relationship with the manufacturer of a commercial product or provider of a commercial service that may be discussed in this presentation.

  3. December 2012 - February 2013

  4. Case Report 80 y/o, ASA 4, Female Procedure: Axillobifemoral Bypass Aug 2011 Acute Inf. Wall MI • Stented • ECHO: EF- 15%, A.I. w/ mild stenosis, LVH • ECG: SR, old inf. Infarct • Previous CABG (LIMA  LAD) • METS 3-4, denies SOB w/ exertion Carotid stenosis (50% bi-lat.) PVD • LUE fatigue/ ischemia? • Claudication Quit Smoking 2009 • 1 ½ PPD x 40+ yrs

  5. Case Report Pre-op Physical Exam Wt: 66kg Ht: 62” BP: 88/42 HR: 67 (S1 S2) RR: 10 (CTA Bi-lat) SpO2: 100% Temp: 99.3 Airway MP2 Upper and lower dentures

  6. Scott Rigdon, CRNA President of Oregon Association of Nurse Anesthetists

  7. Definition: Axillobifemoral Bypass Method of surgical revascularization for the treatment symptomatic aortoiliac occlusive disease for patients without an endovascular option or who cannot undergo an aortofemoral reconstruction.

  8. Axillobifemoral Bypass radiographics.rsna.org, vascularandvein.com 

  9. Medical Tunneler www.goremedical.com 

  10. “What is your anesthetic plan?”

  11. This must have been scheduled in error, we are out in the sticks! • Do we have resources for this? • Oh please let’s cancel case • Transfer the patient to the VA where they are comfortable dealing with this type of pt. population

  12. Options • General Anesthetic • MAC • Regional/ Neuraxial • Combination of above

  13. Plan Isobaric spinal • Anesthetize groin to mid thorax Tumescent (administered by surgeon) • Anesthetize cephalic portions of the surgery MAC (Dexmedetomidinegtt) • Sedation for comfort during the procedure

  14. Isobaric Spinal Anesthesia

  15. CSF Review Adults: ~500ml CSF/ day predominately from choroid plexus • Reabsorbed mostly by arachnoid granulations along sagital sinus • Sagital sinus regulates CSF pressure 5-15 mmHg (Naglehout) academic.kellogg.edu

  16. CSF Review ~140ml CSF present in the subarachnoid spaces, central canal of cord and ventricles of the cord and brain. • 30-80 ml present in spinal canal • variable amongst patients

  17. CSF Density Specific Gravity (ratio): • Density of substance: Density of water S.G. of CSF=1.004 to 1.008 • Vary r/t temperature, location of fluid in subarachnoid space (i.e. S.G. lumbar > ventricles) dependent on proteins present • S.G. 0.001 per ea. degree change in Celsius • S.G. increases w/ age • r/t glucose, protein present in CSF

  18. Baracity Resting position of two fluids w/ differing S.G. when the fluids are mixed (i.e. CSF & LA) Isobaric = (S.G. CSF to LA = ~ 1.004 to 1.008) • Stay in approx same location as injected • Baracity= 1.004 to 1.008 Hyperbaric = (S.G. of L.A. > CSF) • Sink to lowest anatomical position (gravity & positioning) • Baracity > 1.008 Hypobaric = (S.G. of L.A. < CSF) • Float to highest anatomical position • Baracity <1.004

  19. Glass Spine Model www.anesthesia.utoronto.ca

  20. Baracity Clinically change baracity Hypobaric: dissolving drug in sterile water Hyperbaric: dissolving drug in 5-8% dextrose • 0.75% Spinal Bupivicaine Isobaric: dissolving drug in CSF or NS • 0.25%-0.5% Isobaric Bupivicaine • Tetracaine is really the only LA we would reconstitute

  21. Cardiovascular Effects • Sympathectomy & venous pooling  HoTN • T1-T4 cardiac accelerators • Preventative Management: • Co-loading not pre-load • Only 28% of LR remains in the intravascular space at 30min and 20% at 1hr IVC  ISFC (Chestnut) • α-adrenergic vasoconstrictors • Sympathomimetic drugs

  22. Respiratory Effects • Most studies show minimal effects on Vt, RR, min vent and art blood gas tension w/ mid-thoracic level • Phrenic N. rarely paralyzed (C-3,4,5) • Respiratory arrest occurs r/t inadequate perfusion to the medulla • Accessory ABD and intercostals muscles for vent are impaired = inability to cough and clear secretions = aspiration risk • Care to be taken w/ pts that have poor ventilatory ability

  23. My Choice Isobaric spinal • 0.5% spinal Bupivicaine (15mg) w/ 20mcg fentanyl @ L3-4 • Achieved a T-8 sensory block • ~ T-6 sympathetic block & T-10 motor block • Rational: • minimize sympathectomy • prevent respiratory compromise (COPD) Other option was Lumbar epidural • Gradual sympathectomy • Post-op pain management • Not desired by surgeon r/t infection risk, minimal post-op pain, rumored to have had a prior bad outcome

  24. Tumescent Anesthesia www.celebritylaserspa.com

  25. Tumescent Anesthesia Infiltration of large volumes dilute LA subcutaneously Often used in liposuction for its “wetting effect” facilitates fat suctioning, local anesthetic property and decreases blood loss w/ addition of epinephrine

  26. Dosage • 0.05%-0.1% (0.5-1mg/ml) Lidocaine w/ 0.5 to 1.5 mg/L epinephrine • 500-1000mg Lidocaine/ Liter • Addition of sodium bicarbonate may increase absorption, speed of onset and decrease the pain of infiltration • Steroids (Trimcinolone) can be added to decrease scarring and aid healing

  27. Tumescent: Complications • Even though theses are dilute solutions, large amounts of LA may be absorbed leading to toxicity. • Only used minimal amounts for this procedure • Epinephrine slows absorption.

  28. Dexmedetomidine (Precedx) www.precedex.com

  29. Dexmedetomidine- Overview • Presynaptic alpha 2- adrenergic agonist • Sedation & analgesia w/o resp. depression • Not an amnestic • Not GABA-mimetic like propofol or benzodiazepines • Approved by FDA in 1999 for use in ICU setting • Approved in 2008 for patients requiring sedation prior to and or during surgical procedures www.precedex.com

  30. Dexmedetomidine in the OR • Current uses: • Awake fiberoptic intubation • Carotid endarterectomies • Craniotomies • CABGs • Procedural sedation • Bariatric surgery • ICU sedation. • Current studies for its place in OB • Rx preeclamptic patients w/ contraindication to regional anesthesia • Possible increases uterine contractions = aid labor/ prevent uterine atony • Used alone or as co-adjunct to decrease amount of volatile agent and opioids. • Has been used in epidurals (0.5-1 mcg/kg) to improve duration and analgesia.

  31. Pharmacokinetics • Distribution ½ life= 6minutes • Elimination ½ life = 2 hours • 94% protein bound • Almost complete biotransformation in the liver with urinary excretion of 95% • Lower doses required with patients with hepatic or renal disease

  32. Review: Presynaptic Alpha 2 Agonists • Alpha-2 receptors are located presynaptically in sympathetic nerve endings and in noradrenergic neurons in the CNS. • Stimulation of these receptors creates a negative feedback loop and decreases the release of norepinephrine. www.dexmedatomidine.com

  33. What other drug that has been around for a while, works on the pre-synaptic α2-adrenergic receptor?

  34. Alpha 2 Agonist & Sedation The receptors in the locus coeruleus of the upper brain stem and the substantia gelatinosa mediate the sedative effects. www.dexmedatomidine.com

  35. Alpha 2 Agonists & Analgesia Pain is mediated in the spinal cord by alpha 2 receptors inhibiting transmission from nociceptive neurons to relay neurons in the dorsal horn. www.dexmedatomidine.com

  36. Pros of Dexmedetomidine • Sedation and analgesia without respiratory depression • Easily arousable and responsive to stimulation without becoming uncomfortable and quick return to sleep-like state- COOPERATIVE PATIENT • Patients receiving Precedex have been observed to be arousable and alert when stimulated. This alone should not be considered as evidence of lack of efficacy in the absence of other clinical signs and symptoms • Reduced anesthetic/ analgesic requirements • Wide margin of safety

  37. Side Effects • Hypotension, bradycardia and sinus arrest • Atropine and glycopyrolate were effective in treating bradycardia in clinical trails • Should not be administered to those with heart conduction block, hypotension, hypovolemia or shock • Transient HTN seen with loading dose

  38. www.dexmedatomidine.com

  39. What to expect http://www.precedex.com/what-to-expect/

  40. Dexmedetomidine Dosing • Adults: • Loading dose of 1 mcg/kg over 10 min- titrate to effect of sedation desired • Maintenance infusion 0.2-0.7 mcg/kg/min- titrate to desired effect of sedation • If HoTN occurs, decrease/ stop infusion, give fluids, treat w/ vasopressors • Lower doses required w/ hepatic or renal disease • Not indicated for infusion >24hrs • Has not been tested for greater than this time period • Dilute prior to administration: • W/D 2ml of precedex add 48ml of 0.9% NaCl for total of 50ml w/ final concentration of 4mcg/ml

  41. AFOI Protocol www.precedex.com

  42. MAC Protocol www.precedex.com

  43. Conclusion

  44. Thank You!!!

  45. References • Jaffe RA, Samuels SI, Schmiesing CA, Golianu B eds. Anesthesiologist’s Manual of Surgical Procedures. 4th ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2009. • Barash PG, Cullen BF, Stoelting RK, Cahalan M. Clinical Anesthesia. Lippincott Williams & Wilkins; 2009. • Barash P. Handbook of clinical anesthesia. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2009. • Nagelhout JJ, Plaus KL. Handbook of Nurse Anesthesia. Elsevier Health Sciences; 2009. • Morgan GE, Mikhail MS, Murray MJ. Clinical anesthesiology. Lange Medical Books/McGraw Hill; 2005. • Miller, Ronald D, Manuel Pardo, and Robert K. Stoelting. Basics of Anesthesia. Philadelphia, PA: Elsevier/Saunders, 2011. • Fauci AS, Braunwald E, Kasper DL, et al. Harrison’s Principles of Internal Medicine-Harrison’s Online. McGraw-Hill Medical; 2008 • Mills, Stacey E., ed. Sternberg’s diagnostic surgical pathology, 4th ed., Philadelphia: Lippincott Williams & Wilkins, 2004. 2 vol. • Stoelting's Anesthesia and Co-existing Disease, 5th ed. R. L. Hines, and K. E. Marschall. Saunders Elsevier, Oxford, 2008. • Pandharipande PP, Pun BT, Herr DL, et al. Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients: the MENDS randomized controlled trial. JAMA. 2007;298(22):2644-2653.

  46. Aside • Dr. John J. Nagelhout • “>23 factors thought to effect spread of LA in CSF, therefore affecting level and quality of anesthesia.” • “Clinically the most important are the ones that can be manipulated by the provider.” • Total dose of LA • Site of injection • Baracity of drug

  47. Duration • Based primarily on L.A. used and total dose • Highly protein bound drugs (i.e. bupiv, ropiv, tetracaine) long durations of action • Less protein bound drugs (i.e. lidocaine, mepivicaine) shorter duration of action • Ephedrine: vasoconstriction delays normal uptake = prolong duration of L.A. • Greatest w/ Tetricaine, less w/ Lido, minimal w/ Bupiv • Opioids: synergistic effect w/ L.A. and opioids • α2-agonist is not clear but result in prolonged L.A.

More Related